[stock_market_widget type=”card” template=”basic2″ assets=”LAB” realtime=”true” api=”yahoo-finance”]
For most of its existence, Standard BioTools Inc. (NASDAQ: LAB) built its business around the equipment side of life science research. Its instruments, consumables, and services helped biomedical scientists measure proteins and analyze genetic material, the kinds of tools that live in research labs and are sold to universities, pharmaceutical companies, and biotech firms. It was a business grounded in hardware and recurring reagent sales, not the riskier world of developing medicines. That is changing in a fundamental way.
Standard BioTools and Treeline Biosciences, a private clinical-stage oncology company, announced a definitive all-stock merger agreement. Upon completion, which is expected in the second half of 2026, the combined company will operate under the name Treeline Biosciences and trade on Nasdaq under the ticker symbol “TRLN.” This is not a bolt-on acquisition or a minor strategic shift. Standard BioTools is effectively exiting the life science instruments business entirely and becoming something else.
The proposed transaction values Standard BioTools at net cash delivered at closing plus $10 million, estimated at approximately $460 million. The combined company is expected to have more than $900 million in pro-forma cash at closing, which is expected to fund operations into 2029. Standard BioTools contributes roughly $450 million of that cash, the result of earlier asset sales including the divestiture of its SomaLogic proteomics business to Illumina. Pre-merger Standard BioTools stockholders are expected to own approximately 16% of the combined company, with pre-merger Treeline stockholders owning approximately 84%.
The company Standard BioTools is merging with is a different kind of enterprise. Founded in 2021, Treeline has built a productive in-house discovery and development organization that has brought three programs into Phase 1 clinical trials, with a fourth planned clinical entry in 2026. Those three programs are each targeting specific cancer vulnerabilities. TLN-121 is an oral protein degrader designed to remove BCL6 from cancer cells, with early clinical evidence of single-agent activity in heavily pretreated B-cell and T-cell lymphoma patients. TLN-372 is an oral pan-KRAS inhibitor, targeting one of the most common mutations in adult cancers, including lung, pancreatic, and colorectal cancers. TLN-254 is an oral EZH2 inhibitor that was in-licensed following Phase 2 evaluation in China, where it received commercial approval, and is being studied for its combination potential with TLN-121 in aggressive lymphomas. Clinical data readouts from these programs are expected to begin in 2027.
Leading the combined company will be Josh Bilenker, MD, co-founder and Chief Executive Officer of Treeline, who previously co-founded Loxo Oncology and led it through the development of three FDA-approved medicines and its $8 billion acquisition by Eli Lilly. That track record matters to investors evaluating a company at an early clinical stage. Bilenker has done this before, and Treeline’s pipeline reflects a deliberate approach: match specific cancer biology with the right drug format, whether that is a small molecule inhibitor, a protein degrader, or an antibody-drug conjugate.
What happens to the instruments business Standard BioTools is leaving behind? Treeline does not intend to operate Standard BioTools’s Mass Cytometry and Microfluidics businesses, and Standard BioTools is exploring a range of options, including divestitures, to maximize the value of these businesses for stockholders. Standard BioTools shareholders will also receive one contingent value right per share at closing, entitling them to a potential future payment tied to proceeds from those legacy businesses and up to $50 million in earnout payments related to the Illumina transaction. Whether that contingent right pays out anything meaningful depends on how successfully those instrument units are sold.
The backdrop for this announcement carries some weight. On April 20, 2026, Standard BioTools received written notice from Nasdaq that, because its closing bid price had fallen below $1.00 per share for 30 consecutive business days, the company no longer met the minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market. The 8-K filed in connection with the merger agreement notes that Standard BioTools will effect a reverse stock split at closing to address the Nasdaq bid-price deficiency. The merger itself, and the reverse split, would resolve the listing concern as part of the transaction’s mechanics.
The deal still requires approval from Standard BioTools shareholders, regulatory clearance, and other customary closing conditions. Treeline’s board and existing stockholders have already approved it. For investors watching this story, the key dates to track are the shareholder vote, the expected close in the second half of 2026, and the first clinical data readouts from Treeline’s programs beginning in 2027. A company built on selling laboratory hardware is about to become a publicly traded cancer drug developer. Whether that transformation creates the value both sides are betting on will likely take several years to know.
